Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Liabilities (2022 - 2025)

NewAmsterdam Pharma's Total Liabilities history spans 4 years, with the latest figure at $85.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 19.85% year-over-year to $85.9 million; the TTM value through Dec 2025 reached $85.9 million, down 19.85%, while the annual FY2025 figure was $85.9 million, 19.85% down from the prior year.
  • Total Liabilities for Q4 2025 was $85.9 million at NewAmsterdam Pharma, up from $58.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $107.1 million in Q4 2024 and bottomed at -$398.4 million in Q1 2023.
  • The 4-year median for Total Liabilities is $58.4 million (2025), against an average of -$36.3 million.
  • The largest annual shift saw Total Liabilities skyrocketed 119.24% in 2024 before it plummeted 46.45% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $48.0 million in 2022, then rose by 22.26% to $58.7 million in 2023, then skyrocketed by 82.47% to $107.1 million in 2024, then fell by 19.85% to $85.9 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Total Liabilities are $85.9 million (Q4 2025), $58.4 million (Q3 2025), and $36.6 million (Q2 2025).